Strikingly, administration of C3 (AMY101) and C5 targeting drugs (eculizumab) resulted in marked reduction of pro-inflammatory cytokines and improved lung function in SARS-CoV-2-induced COVID-19 [80,81,82]. Here, C5 is linked to COVID-19.